The Unkillable Pathogen: How Acinetobacter baumannii Became Medicine's Most Dangerous Foe

In the hierarchy of drug-resistant pathogens, one organism stands apart. Not because it is the most common — E. coli and Klebsiella infect far more people. Not because it is the most famous — MRSA dominates headlines. But because it is, by almost every clinical measure, the hardest to treat and the most lethal when it strikes.

Acinetobacter baumannii — specifically its carbapenem-resistant form, CRAB — is the WHO's #1 critical priority pathogen. It sits at the top of the list for a reason: when CRAB reaches the bloodstream, mortality rates exceed 40%. In ventilator-associated pneumonia — its signature infection — mortality can reach 60%. These numbers have barely changed in two decades.

This is the first in a series profiling each of the six ESKAPE pathogens. I start with A. baumannii because it represents the extreme case — the pathogen where resistance is most complete, treatment options most limited, and the need for new drugs most acute. But also because, for the first time in fifty years, the pipeline is genuinely responding.

The Biology of an Extremophile

Most bacteria die within hours on a dry hospital surface. A. baumannii survives for weeks to months. Studies have documented survival on dry surfaces for over 27 days regardless of whether the strain comes from outbreaks or sporadic infections. Individual endemic strains have persisted in hospitals for up to 3 years.

This extraordinary desiccation tolerance — rivalling tardigrades — stems from multiple molecular mechanisms. The global regulator BfmR induces stress responses that promote survival on surfaces and during infection simultaneously. The post-transcriptional regulator CsrA controls both desiccation tolerance and biofilm formation. And intrinsically disordered proteins — similar to those used by tardigrades to survive extreme environments — may represent strategies not previously seen in bacteria.

The organism can be found on tables, ventilators, bed rails, door handles, telephones, computers, hand sanitizer dispensers, and the gowns of healthcare workers. It forms robust biofilms on medical devices — structured communities encased in a protective polymeric matrix that shields bacteria from antibiotics and the immune system. Key biofilm genes like bap, csuE, and ompA are nearly universal in clinical isolates.

The combination of desiccation tolerance, biofilm formation, and multidrug resistance makes A. baumannii uniquely adapted to the hospital environment. It is, in the most literal sense, a creature of the ICU — thriving in the exact conditions we create to save the sickest patients.

The Resistance Architecture

Where most pathogens rely on one or two resistance mechanisms, A. baumannii deploys them all simultaneously. Understanding this architecture is essential to understanding why CRAB is so difficult to treat — and why certain pipeline candidates may succeed where others have failed.

The OXA Carbapenemases: A. baumannii's Primary Shield

The dominant mechanism of carbapenem resistance in A. baumannii is not the NDM or KPC metallo-β-lactamases that threaten Klebsiella and E. coli. Instead, CRAB relies primarily on Class D OXA-type β-lactamases — a family of serine-dependent enzymes that hydrolyze carbapenems and cannot be inhibited by traditional β-lactamase inhibitors like clavulanic acid or tazobactam.

The numbers tell the story: acquired OXA-type carbapenemase genes are found in 96% of CRAB isolates globally, with OXA-23 by far the most common. OXA-24/40 dominates in specific regions (Iberian Peninsula, some South American countries), while OXA-58 appears sporadically. Every A. baumannii isolate also carries the intrinsic OXA-51, which normally has weak carbapenemase activity — but when the insertion sequence ISAba1 inserts upstream, it dramatically upregulates expression, converting a dormant gene into an active resistance mechanism.

This ISAba1-OXA interplay is central to CRAB's biology. The insertion sequence acts as a molecular switch, amplifying OXA expression through promoter provision. The more mobile elements present, the higher the resistance. And these elements can be chromosomal or plasmid-borne, ensuring both vertical and horizontal transmission.

The Outer Membrane: A Natural Fortress

A. baumannii has naturally fewer and smaller porins than other Gram-negative bacteria — a structural feature that restricts drug entry independent of any acquired resistance. Loss of porins like CarO and Omp29 further reduces permeability, working synergistically with OXA enzymes: less drug gets in, and what enters is destroyed.

Perhaps most remarkably, CRAB can spread resistance to other species through outer membrane vesicles (OMVs) — small blebs shed from the cell surface that carry active OXA-23 and OXA-24/40 enzymes. These vesicles can protect E. coli and P. aeruginosa against carbapenems in polymicrobial infections — a communal defense system that extends beyond species boundaries.

The Efflux Arsenal

Three major RND-family efflux pump systems — AdeABC, AdeIJK, and AdeFGH — provide broad-spectrum drug expulsion. AdeABC alone can pump out aminoglycosides, fluoroquinolones, tetracyclines, and chloramphenicol. When overexpressed alongside OXA enzymes and porin loss, these pumps create a layered defense that defeats most antibiotic combinations.

The Pipeline Revolution

For decades, the CRAB pipeline was essentially empty. Clinicians relied on colistin — a toxic, 60-year-old drug pulled from the shelf as a last resort — and hoped for the best. In the last three years, that has changed dramatically.

Xacduro: The First New Standard of Care

Sulbactam-durlobactam, approved by the FDA in April 2023, was the first drug specifically developed for CRAB infections. The design is elegant: sulbactam has intrinsic activity against A. baumannii (targeting PBPs 1 and 3), but OXA enzymes destroy it. Durlobactam, a diazabicyclooctane (DBO) β-lactamase inhibitor, neutralizes Class A, C, and D enzymes — including the OXA carbapenemases that define CRAB.

The ATTACK Phase 3 trial showed 19% 28-day mortality versus 32% with colistin — a 13-percentage-point absolute reduction — with dramatically less nephrotoxicity (13% vs 38%). In patients with colistin-resistant CRAB, 28-day mortality was just 18%. Resistance rates remain remarkably low: 0–5.2% of CRAB isolates in global surveillance.

Xacduro is now the IDSA-preferred treatment for CRAB infections. But it is approved only for HABP/VABP in the US, and the EMA has not yet granted approval. Real-world evidence beyond case reports remains limited.

Cefiderocol: The Trojan Horse Under Siege

Cefiderocol was a breakthrough concept: a cephalosporin conjugated to a siderophore that hijacks bacterial iron uptake systems, bypassing the outer membrane fortress entirely. Approved in 2019, it has activity against CRAB, but a 2026 study from Hackensack Meridian CDI revealed the alarming complexity of emerging resistance.

Using genome-wide transposon mutagenesis, Rome et al. identified ten genes whose disruption reduces cefiderocol susceptibility — spanning siderophore uptake (pirA, puiA), oxidative stress responses (oxyR, nfuA), and cell envelope morphogenesis (mreB). Resistance is not merely about blocking iron transport — it involves an intricate interplay of multiple molecular pathways. The bacteria are outflanking the Trojan horse through convergent evolution.

Zosurabalpin: A New Class for a New Era

If approved, zosurabalpin would be the first genuinely new antibiotic class for Gram-negative bacteria in approximately fifty years. A tethered macrocyclic peptide (MCP) discovered through screening ~45,000 compounds, it blocks the LPS transport machinery (LptB₂FGC complex) — preventing lipopolysaccharide from reaching the outer membrane, which is lethal to the bacterium.

Critically, zosurabalpin's mechanism is entirely orthogonal to existing resistance. OXA enzymes, efflux pumps, porin loss — none of the standard CRAB defenses apply. Resistance mutation rates are exceptionally low (10⁻⁷ to <10⁻⁹). The Phase 3 trial is enrolling approximately 400 patients with invasive CRAB infections at sites across Europe, the Americas, and Asia, comparing zosurabalpin to standard of care.

BV100: The Rifabutin Surprise

The most recent addition to the CRAB pipeline came on March 16, 2026, when the FDA cleared BioVersys's BV100 for Phase 3. BV100 is an IV formulation of rifabutin — an old drug from the rifamycin class — but with a newly discovered active uptake mechanism into A. baumannii. For the first time, rifabutin can reach effective concentrations inside Gram-negative bacteria, targeting RNA polymerase through a completely different mechanism than zosurabalpin.

The Phase 2 data are striking: combined with polymyxin B, BV100 achieved a 50% relative reduction in 28-day all-cause mortality — from 60% (best available therapy) to 25% — in CRAB ventilator-associated pneumonia. The Phase 3 RIV-TARGET trial will enroll 300 patients across the US, Europe, Latin America, Asia, and China. Readout is expected in late 2027.

Beyond Small Molecules

The conventional pipeline is only part of the story. Several unconventional approaches target CRAB biology through mechanisms that traditional antibiotics cannot.

Pseudaminic Acid Antibodies: Targeting a Bacterial Sugar

In February 2026, a collaboration between the University of Sydney, WEHI, and the University of Melbourne published a remarkable finding in Nature Chemical Biology. They developed a pan-specific antibody targeting pseudaminic acid — a sugar found on bacterial surfaces but absent in human cells. In a mouse model of MDR A. baumannii infection, the antibody achieved 100% survival. This passive immunotherapy approach could be particularly valuable for ICU patients and the immunocompromised, who cannot mount their own immune response quickly enough.

Colistin Heteroresistance and Collateral Sensitivity

A 2026 study in the Journal of Antimicrobial Chemotherapy by Sancak et al. revealed that 32.2% of CRAB bloodstream isolates harbor colistin heteroresistance — subpopulations with different resistance levels within a single infection. The resistant subpopulation carries lpxD deletions, which — crucially — create collateral sensitivity to tetracyclines, macrolides, and aminoglycosides. The same mutations that enable colistin resistance create new vulnerabilities.

This connects to the broader evolutionary exploitation strategies I covered earlier. In CRAB, the trade-off is biologically clear: LPS modification for colistin resistance compromises outer membrane integrity, opening doors for drugs that were previously excluded. The clinical challenge is detecting these subpopulations — standard AST misses them entirely.

Exosome siRNA: Gene Silencing Across Kingdoms

Zhang's lab at Nanjing published what may be the first demonstration of RNA interference working in bacteria (Cell Reports Medicine, March 2025). They loaded exosomes with siRNA targeting mecA (in MRSA), achieving 70% mouse survival through translational silencing. The same approach could theoretically target OXA genes in CRAB — silencing the very enzymes that define carbapenem resistance. This is early-stage work, but it represents a fundamentally new axis of attack: rather than designing molecules to evade resistance, disable the resistance machinery itself.

Phage Therapy for CRAB

Phage therapy trials targeting A. baumannii are expanding rapidly. One intriguing finding: clinical antibiotic-resistant CRAB strains show higher susceptibility to environmental phages than antibiotic-sensitive strains — resistance to drugs and resistance to phages appear to be inversely correlated. The Phab24 phage system demonstrates the phage steering concept specifically in A. baumannii: phage-resistant mutants lose capsule, becoming more vulnerable to colistin and immune clearance.

The Geography of CRAB

CRAB is not distributed equally. Carbapenem resistance rates in A. baumannii exceed 70–80% across much of China and Southeast Asia, where the organism is the leading cause of death attributable to antimicrobial resistance. In the US, carbapenem resistance is found in 41–53% of ICU Acinetobacter isolates and 75–77% of long-term acute care hospital isolates. In Europe, rates vary dramatically — from under 5% in Scandinavia to over 80% in Greece and parts of Southern Europe.

This geography matters for the pipeline. BV100's Phase 3 trial specifically includes sites in China and Asia, where the burden is greatest and carbapenem resistance reaches 60–80%. Zosurabalpin's global enrollment captures all major regions. But access remains the fundamental question: even if both drugs succeed, will they reach the ICUs in Southeast Asia and sub-Saharan Africa where CRAB kills the most people?

"When caused by carbapenem-resistant strains, mortality rates can reach up to 50%. CRAB infections are a serious health threat throughout the world, with incidence rates particularly high in China and Asia."

— BioVersys, FDA Phase 3 announcement, March 16, 2026

What This Pathogen Teaches Us

A. baumannii is a case study in convergent resistance. It does not rely on a single mechanism — it stacks them. OXA enzymes destroy drugs. Reduced porins block drug entry. Efflux pumps expel what gets through. Biofilms create physical sanctuaries. Mobile elements spread the genes. And desiccation tolerance ensures the organism persists in the environment between patients, ready to colonize the next vulnerable host.

This stacking is why monotherapy fails, why standard β-lactamase inhibitors are irrelevant, and why the only approved drugs that work are those specifically designed to overcome CRAB's particular defenses — durlobactam's DBO architecture targeting OXA enzymes, cefiderocol's siderophore Trojan horse bypassing porins.

It is also why the pipeline news matters so much. Two Phase 3 candidates with entirely novel mechanisms — LPS transport (zosurabalpin) and active bacterial uptake of RNA polymerase inhibitors (BV100) — represent the first time in the history of this pathogen that multiple genuinely new approaches are being tested simultaneously in late-stage trials. Behind them, passive immunotherapy (pseudaminic acid), outer membrane targeting (darobactin D22), and evolutionary exploitation (phage steering, collateral sensitivity) offer additional axes of attack.

The CRAB pipeline went from essentially zero to six candidates across four distinct mechanisms in three years. Whether this translates into drugs that reach patients will depend on the same broken economics that have killed companies with positive clinical data before. But the science, for the first time, is genuinely ahead of the pathogen.

For the deadliest member of the ESKAPE consortium, that is no small thing.